Scientists have successfully used CRISPR-Cas9 gene editing to remove HIV DNA from human immune cells, marking a breakthrough in the fight against HIV/AIDS.
A therapy called EBT-101, developed by Temple University and Excision BioTherapeutics, was able to target and cut out latent HIV proviral DNA in lab and animal models.
Early clinical trials in humans showed the treatment was safe and well-tolerated, though HIV rebounded after patients stopped standard antiretroviral therapy — suggesting the treatment still needs refinement.
Separately, researchers in the Netherlands (Amsterdam UMC) also confirmed that CRISPR could eliminate HIV from infected cells in lab settings by targeting highly conserved parts of the virus genome.
While not yet a cure, this progress represents a major step toward a potential one-time genetic treatment for HIV.
More research is ongoing to improve effectiveness and ensure safety for wider use.
Scientists have successfully used CRISPR-Cas9 gene editing to remove HIV DNA from human immune cells, marking a breakthrough in the fight against HIV/AIDS.
A therapy called EBT-101, developed by Temple University and Excision BioTherapeutics, was able to target and cut out latent HIV proviral DNA in lab and animal models.
Early clinical trials in humans showed the treatment was safe and well-tolerated, though HIV rebounded after patients stopped standard antiretroviral therapy — suggesting the treatment still needs refinement.
Separately, researchers in the Netherlands (Amsterdam UMC) also confirmed that CRISPR could eliminate HIV from infected cells in lab settings by targeting highly conserved parts of the virus genome.
While not yet a cure, this progress represents a major step toward a potential one-time genetic treatment for HIV.
More research is ongoing to improve effectiveness and ensure safety for wider use.
English
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Arabic